Combined preparations . A number of trials have been carried out with implants containing two hormones. The combination of an oestrogen with an anabolic steroid, or with progesterone, has met with the greatest responses. Synovex-S has consistently increased gain as well as FCE, with responses averaging about 20% and 17% respectively (20, 21, 22, 34, 35, 36, 37, 42, 43, 44, 45, 46, 47, 48). Hexoestrol + TBA (usually 30 or 45 mg hexoestrol + 300 mg TBA) has resulted in marked increases in gain (24, 25, 26, 29, 49, 50, 51, 52, 53), of the order of 30% and in FCE (25, 49, 50, 51, 53) of the order of 20%. Oestradiol-17β + TBA (20/140 mg) has given similar results (27, 28, 37, 54, 55), as has Zeranol + TBA (36/300 mg), also recently tested (27, 37, 38, 39, 40, 41, 56).
Dienogest was synthesized in 1979 in Jena , Germany under the leadership of Kurt Ponsold, was initially referred to as STS-557 .   It was found that its potency was 10 times that of levonorgestrel .  The first product on the market to contain dienogest was a combined oral contraceptive pill (with ethinylestradiol), Valette, introduced in 1995 and made by Jenapharm .  In 2007, dienogest was introduced as Dinagest in Japan for the treatment of endometriosis, and it was subsequently marketed for this indication as Visanne in Europe and Australia in December 2009 and April 2010, respectively.  Qlaira was introduced in Europe in 2009 and Natazia was introduced in the United States in 2010. 
It shall be noticed, that in men, approximately 5% of testosterone undergoes 5α-reduction to form the more potent androgen, dihydrotestosterone (DHT), also known as androstanolone. From another side approximately % of testosterone is converted into estradiol (the primary female sex hormone) by aromatase an enzyme expressed in the brain, liver, and adipose tissues. Hence, don`t forget to take precautions to avoid respective side effects. Thereof we recommend to perform blood works and take aromatase inhibitors on cycle (if required, anastrozole preferably) and SERMs (clomifene, toremifene) during post cycle therapy (PCT).